Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia.
Where this comes from
- Record sourced from PubMed, PMID 36260990.
- Also identified by DOI 10.1016/j.xcrm.2022.100790 and PMC identifier 9589095.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kuo and colleagues<sup>1</sup> evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion-dependent α-thalassemia or β-thalassemia. The high rate of hemoglobin response and good tolerability encourages further development in thalassemia.
Medical subject headings
- beta-Thalassemia